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1. Introduction 
The census of cancer genes (http://www.sanger.ac.uk/genetics/CGP/Census/) includes 487 
mutated genes (data on September 2012) manually curated from the scientific literature, 
which are proved to induce or accelerate cancer development when appropriately changed 
(point mutations, deletions, translocations or amplifications) (see criteria for inclusion in the 
cancer gene census in [1]). Studies in mice have magnified the number of the potential 
cancer genes to more than 3000 [2] and the number of mutated genes revealed in tumor 
sequencing studies are gradually approaching this number (NCG 3.0, http://bio.ifom-ieo-
campus.it/ncg) [3, 4]. Nevertheless, despite the impressive data accumulated from studies of 
gene mutations and pathway alterations, an overwhelming amount of diverse molecular 
information has offered limited understanding of the general mechanisms of cancer [5, 6]. 
For decades tumor development from precancerous lesions to obvious malignancy and 
metastases has been considered as a result of deterministic sequential accumulation of 
mutations in the handful of “driver” cancer genes, occurring in a continuous linear pattern 
of cancer progression, while genome/karyotype changes were judged as a by-product of 
transformation (see ref. in [5-10]). However, only a few genes have been shown to be 
commonly mutated in cancer sequencing studies, and they are neither highly prevalent nor 
in multiple tumor types [11-14]. Furthermore, the whole exome sequencing of multiple 
spatially separated samples obtained from the same tumor followed by phylogenetic 
reconstruction of tumor progression has revealed significant intratumoral heterogeneity 
with “no dominant clones in the cancer tissue” [15], “punctuated clonal evolution… without 
observable intermediate branching” [16] or “branched evolutionary tumor growth” with 63 
to 69% of all somatic mutations not detectable across every tumor region and some genes 
undergoing multiple distinct and spatially separated inactivating mutations within a single 
tumor [17]. High-resolution SNP array of B-cell chronic lymphocytic leukemia (B-CLL) has 
demonsterated “clearly a nonlinear, branching sub-clonal hierarchy in B-CLL with multiple 
ancestral subclones” [18]. Similarly, it has been concluded that CLL progression can occur in 
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“either a linear or branching manner, with multiple genetic subclones evolving either in 
succession or in parallel” [19]. Evaluation of the clonal relationships among pancreatic 
cancer metastases and primary tumor has led to conclusion that the genetic heterogeneity of 
metastases reflects heterogeneity already existing within the primary carcinoma, and that 
the primary carcinoma is a mixture of numerous subclones [20]. Thus, as Cahill et al [21] 
point out, “The tumor is clonal only in the sense that all cells within a tumor are derived 
from the same cell precursor. Genetic instability makes the tumor itself a population under 
change – a huge collection of coexisting subclones, each with the potential for future 
changes in the face of selective pressures”. Altogether, these data seriously contradict to 
deterministic sequential accumulation of mutations in the handful of “driver” cancer genes 
occurring in a continuous linear pattern of cancer progression postulated by conventional 
gene mutation theory of cancer.  
In contrast, chromosome instability (CIN) and the resulting magnitude of intratumor 
clonal/non-clonal heterogeneity are recognized to be the main driving forces of tumor 
evolution (immortalization, transformation, metastasis, acquisition of drug resistance) 
(reviewed in [5-10]). CIN results from persistent defects in mitotic fidelity and implies both 
whole chromosome instability and segmental chromosome instability (translocations, 
deletions, and amplifications). Although defects in telomere maintenance, sister chromatid 
cohesion, kinetochore-microtubule attachments, assembly of amphitelic bipolar mitotic 
spindles, as well as translocations containing breakpoints within fragile sites, instability of 
satellite repeats in heterochromatin, cell-in-cell formation by entosis (as a result, cytokinesis 
frequently fails, generating binucleate cells that produce aneuploid cell lineages) and 
random fragmentation of the entire chromosome (chromothripsis) in which chromosomes 
are broken into many pieces and then randomly stitched back together can contribute to 
CIN during tumor evolution, in established cancer cell lines mechanism of centrosome 
amplification and clustering is proposed to be the major contributor to CIN (discussed 
below). It is documented that extreme CIN relative to tumors with intermediate CIN is 
associated with improved survival outcome in cancer and experimental models have 
evidenced that extreme CIN has a negative impact on cellular fitness, generating 
nonneoplastic and nonviable cells, and constrains tumorigenesis. However, CIN represents 
early and causative event in cancer progression and significantly correlates with 
tumorigenic potential of cells and such clinical variables as tumor progression from 
precancerous lesions to malignant tumors and then to metastases, survival, treatment 
sensitivity, and the risk of acquired therapy resistance (reviewed in [22]).  
In this review we provide evidence that tumorigenic action of cancer genes or mutagenic 
and non-mutagenic carcinogens is directly linked to centrosome deregulation and CIN. Any 
factors or stresses that contribute to CIN inevitably promote the evolution of cancer. CIN 
and clonal/non-clonal intratumor heterogeneity are the interconnected driving forces of 
immortalization and transformation and the reasons of oncogene addiction independence of 
tumors from any particular oncogene and general ineffectiveness of targeted therapy in 
clinic.  
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2. Immortalization and transformation: The central role of karyotype 
Comparing gene expression in glioblastoma, the most aggressive form of human brain 
tumors, to the normal brain cells we have found CHI3L1 among the genes with the highest 
expression level in glioblastomas [23, 24]. Addition of CHI3L1 to cell medium increased 
mitogenic and proliferative properties of 293 cells (human embryonic kidney 293 cells, also 
often referred to as HEK293) [25, 26]. 293 cells stably transfected with CHI3L1 have an 
accelerated growth rate relatively to the parental cells and can undergo anchorage-
independent growth in soft agar that is one of the consistent indicators of oncogenic 
transformation [25, 27]. Furthermore, 293_CHI3L1 cells implanted in the rat brain of adult 
immunocompetent animals have given rise to the large intracerebral tumors with the newly 
ingrown blood vessels [27, 28].  
Previously, similar data on transformation of immortalized 293 cells by one gene 
transfection was obtained for multiple diverse genes (see ref. in [29, 30]). However, 293 cells 
themselves (the same as many other cell lines) are already immortalized. In a given case, 
ectopic expression of CHI3L1 alone results in the tumorigenic conversion of previously 
immortalized 293 cells with shared adenovirus 5 DNA [31]. An immortalized cell (as well as 
a normal cell) must acquire a number of chromosome changes to become a fully malignant 
tumor cell. Karyotype analysis of 293_CHI3L1 clones have shown that these cells differ from 
wild type [31, 32] and control cells (293_pcDNA3.1) in modal chromosome number and 
structure of chromosomes (manuscript in preparation). Other authors have also shown that 
overexpression, for example, of tripeptidyl-peptidase II [33], EBNA1 binding protein 2 [34], 
GLI1 transcripton factor [35] or Cut homeobox 1 trancription factor [36] have triggered 
centrosome and chromosomal abnormalities in 293 cells.  
Transformation with one oncogene is not cell type-spesific. Analysis of literature has 
revealed that different oncogenes with diverse and nonoverlapping intracellular functions 
are characterized by the same ability: to trigger conversion of immortalized cells (e.g., 293, 
NIH3T3, HMEC, MCF10A, HCT116) or even primary cells into malignant tumor cells or 
aggravate tumorigenicity of tumor cells (reviewed in [30]). What is the basis for cell 
immortalization and how do different cancer genes trigger conversion of immortalized and 
even primary normal cells into malignant tumor cells in vitro and in vivo? Overcoming of 
senescence and acquisition of immortality is an essential rate-limiting step in the process of 
malignant transformation of mammalian somatic cells. In vitro immortalization of various 
cell types was successfully implemented by the introduction of viral genomes/oncogenes, 
ectopic expression of human telomerase reverse transcriptase (hTERT), some transcription 
factors (e.g. c-MYC, BMI1, ZNF217, or β-catenin), or carcinogen treatment, whereas 
spontaneously immortalized cells emerge at an extremely low frequency in vitro (about 10−7) 
[30]. Multiple investigations have revealed that irrespectively of the nature of 
“immortalizing/transforming agent” for immortalization/transformation in vitro cells must 
overcome cellular senescence by inactivating/dysregulating p16INK4A-pRB and/or ARF-p53 
pathways and maintaining their telomeres by activation of hTERT expression (a 
predominant way) or by an alternative mech
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However, in vivo research has shown that telomerase-deficient primary mouse embryonic 
fibroblasts (MEFs) have generated tumors in nude mice following transformation [37]. 
Transformation of human primary fibroblasts and human primary mesodermal cells has 
resulted in cells capable to form colonies in soft agar and tumors in mice but they and the 
majority of the tumors derived from them have lacked telomerase activity, and telomere 
erosion has been observed [38]. To the point, human primary melanomas show telomere 
maintenance as a late event in tumor progression (metastatic melanoma); thus, telomere 
maintenance/immortalization is associated with progression rather than initiation of 
melanoma [39]. Moreover, approximately 40% of glioblastomas have no defined telomere 
maintenance mechanism (nither telomerase expression nor the alternative lengthening of 
telomeres mechanism) [40]. Numerous studies have proved that telomere dysfunction in the 
absence of telomerase activity drives chromosomal instability/karyotype evolution through 
telomere-telomere type rearrangements (breakage-fusion-bridge cycles) promoting the 
appearance of chromosomal rearrangements and numerical chromosome aberrations, 
contributing to genomic intratumor diversity and favoring cell immortalization, the 
acquisition of a tumor phenotype and increased metastasis [41-46] 
Studing karyotype evolution in both individual cells and cell populations during various 
stages of cellular immortalization process in in vitro cell culture model it has been revealed 
that the karyotype evolution with the complex interplay between clonal and non-clonal 
chromosome abberations serves as the driving force for immortalization. By repeating the 
same experiments or analyzing the parallel clones derived from the same initial cell 
population, it has been found out that the immortalized cells display unique distinctive 
karyotypes, demonstrating the stochastic nature of karyotype evolution during cellular 
immortalization (reviewed in [5, 10]). Additional follow-up experiments have demonstrated 
that genome-based evolution can be detected in most of the major transition steps in cancer 
including immortalization, transformation, metastasis, and drug resistance [5]. Similarly, 
analyzing the karyotypes of clonal tumorigenic cell lines arising from the mass cultures of 
human cells within months after transfection with the same set of artificially activated 
oncogenes it has been found that different tumorigenic cell lines had individual clonal 
karyotypes and phenotypes and the phenotypes and karyotypes of different tumors 
induced by these lines in different mice have been karyotypic and phenotypic variants of the 
parental prototypes [47].  
Thus, the process of immortalization/transformation is not simply a number of well defined 
events like inactivation of cell cycle negative regulators (p16INK4A-pRB and/or ARF-p53) and 
activation of telomerase (hTERT) but, instead, is associated with karyotype/genome 
abnormalities (structural and numeral aneuploidy as well as abberant methylation and gene 
mutations) and, as a consequence, with global changes in gene expression and function. 
Analysis of 45 spontaneously transformed murine cell lines from normal epithelial cells has 
demonstrated that supernumerary centrosomes, aneuploidy and CIN precedes 
immortalization and transformation [48]. Also, CIN precedes chemical induced malignant 
transformation [7-9]. All immortalized and malignantly transformed cells have abnormal 
karyotypes irrespectively of “immortalizing/transforming agents”, and karyotype evolution 
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plays the central role in immortalization, transformation, metastasis, and drug resistance 
(reviewed in [5-10, 22, 30, 47, 49-52]). 
3. Tumor genome profile output 
In 2008 The International Cancer Genome Consortium (http://www.icgc.org/icgc) stated the 
primary goal to comprehensively characterize over 25,000 cancer genomes from 50 different 
cancer types and/or subtypes at the genomic, epigenomic, and transcriptomic levels to 
reveal the repertoire of oncogenic mutations and signaling networks, which can be exploited 
for the development of new cancer therapies [53]. Thus, “designed to identify the Achilles’ 
heel of cancer” [54] and “driver universal cancer genes” [55] whole exome and genome 
sequencing studies (see ref. in [3, 4]) instead have revealed a large number of stochastic gene 
mutations in solid tumors for each individual with the same cancer type [11-14]. Searching 
for the “universal” cancer genes among deleted, amplified and sequence mutated genes 
across breast, colon, pancreatic cancers and glioblastoma has shown that only one gene, 
TP53, is commonly mutated in all four major cancer types [55, 56] and no single gene is 
commonly deleted or amplified [55]. Similarly, from more than 1,000 mutated genes 
identified across whole exome or genome sequencing of 10 tumor types, only 46 genes have 
been found mutated in two types, 7 (TP53, CDKN2A, RB1, PIK3CA, KRAS, NF1, and 
KIAA0774) in three types and only 1 (TP53) in four types (in 6 types) [3]. Ongoing Cancer 
Cell Line Project (http://www.sanger.ac.uk/genetics/CGP/CellLines/), which target is to 
sequence all known cancer genes in ~800 cell lines, has confirmed that TP53, CDKN2A, RB1, 
PTEN, PIK3CA, KRAS, and BRAF are the most frequenly mutated genes. 
Interestingly, analysis of 70 tyrosine kinases with altered gene expression or located at a 
genomic site of copy number gain or loss in 95 chronic lymphocytic leukemias (CLLs) has 
revealed no somatic mutations [57]. Extension of this research, sequencing of 515 kinase 
genes in 23 CLLs, has revealed only six somatically acquired mutations (e.g., in RAS and 
RAF) across all kinase genes [58]. Further B-RAF sequencing in 250 CLLs has detected four 
B-RAF mutations, none involving B-RAF amino acid residue 600, which is the predominant 
B-RAF mutation found across human tumors. N-RAS mutations were found in 2 cases and 
none of K-RAS among 234 CLLs analyzed [58].  
High-resolution analysis of somatic copy-number alterations (SCNAs) from 3,131 cancer 
specimens, belonging largely to 26 histological types, revealed a total of 75,700 gains and 
55,101 losses across the cancers, for a mean of 24 gains and 18 losses per sample [59]. An 
average of 17% of the genome was amplified and 16% deleted in a typical cancer sample. 
From all SCNAs only 158 regions of focal SCNA were altered at significant frequency across 
several cancer types, of which 122 could not be explained by the presence of a known cancer 
target gene located within these regions [59]. High-resolution aCGH analysis of 598 human 
cancer cell lines derived from 29 different tissues revealed 2424 amplifications and 14010 
deletions across the entire cell line panel [60]. SNP array screening of 746 cancer cell lines 
identified 2428 somatic homozygous deletions, which overlie 11% of protein-coding genes 
[61]. These cell lines have also been sequenced for mutations in the coding exons of 46 
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known cancer genes. In total, 1753 putative oncogenic mutations were identified [61]. 
Another research group identified 2576 somatic mutations across 1507 coding genes from 
441 tumors comprising breast, lung, ovarian and prostate cancer types and subtypes [62].  
Thus, the list of “non-universal” cancer genes and mutations within them is growing 
proportionally to seqencing studies stuffing databases. The Network of Cancer Genes (NCG 
3.0, http://bio.ifom-ieo-campus.it/ncg) collects information on hundreds of cancer genes that 
have been found mutated in 16 different cancer types [4]. These genes were collected from 
the Cancer Gene Census as well as from 18 whole exome and 11 whole-genome screenings 
of cancer samples (see referenses in [3, 4]. COSMIC database (http://www.sanger. 
ac.uk/genetics/CGP/cosmic/) combines cancer mutation data manually curated from the 
scientific literature with the output from the Cancer Genome Project [63, 64]. COSMIC 
catalogues all somatic mutations in benign and malignant tumors as well as tumor cell lines 
[65]. Release v61 (September 2012) includes 22170 genes, 405271 mutations (224649 unique 
mutations), and 8931 gene fusions, described in 773098 tumor samples (2556 whole 
genomes).  
It is worth noting that the total number of mutations in tumor samples are significantly 
underestimated, as the current methods of DNA sequencing detect a single base change 
only if it presents in >10% of the molecules, that is, therefore predominately clonal 
mutations [14]. Methodologies for studing patterns of genomic changes (e.g., aCGH and 
SNP) also detect only dominant clonal aberrations [10]. Estimate of all mutations including 
sub-clonal and random suggests that each cancer cell within most tumors contains >10,000 
mutations and by the time a tumor is clinically detected (108–109 cells) it might harbour >1011 
different mutations [14].  
Importantly, genome profiling of a tumor bulk produces average profile of genetic changes 
in a tumor sample and does not mirror heterogeneity of genetic changes within tumor 
sample, i.e., changes restricted to the separate populations of tumor cells or single tumor 
cells [66]. However, there is a high level of genomic and (epi)genetic heterogeneity within 
individual lesions, as well as between primary tumors, metastatic cells, and relapses (see ref. 
in [22]). 
4. Cancer genes induce, promote and licence CIN 
CIN/random aneuploidy and intratumor heterogeneity drive tumor evolution. Which 
should surveillance mechanisms be disrupted to unleash CIN? As it follows from tumor 
sequencing studies, beyond the overwhelming “mutator phenotype”, the most altered 
signaling pathways within and across different cancer types are p14ARF-p53 pathway 
(CDKN2A/ARF and TP53 genes), p16INK4A-pRB pathway (CDKN2A/INK4A and RB1 genes), 
MAPK pathway (NF1, KRAS, and BRAF genes) and PI3K-AKT pathway (PTEN and PIK3CA 
genes).  
CIN results from persistent defects in mitotic fidelity and is strongly favored in cells with 
disrupted p14ARF-p53 and/or p16INK4A-pRB pathways explaining their highest deregulation 
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frequency in immortalized and tumor cells [29]. Patients with Li-Fraumeni syndrome 
characterized by germline mutations of TP53 develop a wide range of malignancies 
(reviewed in [67]). Mice expressing the TP53 mutants have increased incidence of sarcomas 
and carcinomas (reviewed in [68, 69]). In contrast, "super TP53" mice, carrying TP53 alleles 
in addition to the two endogenous alleles, exhibit an enhanced response to DNA damage 
and are significantly protected from cancer when compared with normal mice [70]. Cancer 
patients with missense mutations in TP53 often have a poorer prognosis than those lacking 
TP53 entirely, as the presence of dominantly mutated p53 not only confers loss of tumor 
suppressor activity but also provides a gain of oncogenic function [68, 71]. P53 gain of 
oncogenic function mutants have enhanced oncogenic potential and effectively induce CIN 
[68, 69, 72]. In vitro and in vivo data have established that loss of p53 activity and, to a greater 
degree, dominantly mutated p53 is the major event responsible for increased expression of 
cell-cycle and proliferation-associated genes (reviewed in [73]). The presence of disrupted 
TP53/dysregulated p53 pathway is significantly associated with intratumor genetic 
heterogeneity/clonal diversity [74], radio- and (multi)drug resistance [75-78]. Strikingly, 
high-grade serous ovarian cancer is characterized by TP53 mutations in 96% of tumours (303 
of 316 samples analysed) [79], and TP53 is the most frequently known altered gene in acute 
myeloid leukemias with complex karyotype (CK-AML) [80]. Multivariable analysis of 234 
CK-AMLs revealed that TP53 alteration (70% of samples) was the most important 
prognostic factor in CK-AML, outweighing all other variables [80]. Evaluation of CIN in 
Barrett's esophagus tissue has revealed that CIN is highly correlated with TP53 LOH [81]. In 
agreement, patients with LOH in TP53 are 16 times more likely to progress from 
premalignant Barrett’s esophagus to esophageal adenocarcinoma than patients without 
TP53 LOH, supporting the hypothesis that expansion of CIN clones drive malignancy [82, 
83]. Moreover, usage of integrated DNA sequence and copy number information to 
reconstruct the order of abnormalities in individual cutaneous squamous cell carcinomas 
and serous ovarian adenocarcinomas have allowed to reveal that loss of the second TP53 
allele appears to precede not only the development of CIN but also a vast expansion of 
simple mutations [84]. Mutation in TP53 is the most common genetic alteration reported 
during metastasis to the brain in breast cancer [85]. Analysis of breast cancer cell line MCF-7 
variant overexpressing a dominantly mutated TP53 have showed that impaired p53 
function drives breast cancer progression by CIN, which generates karyotypic variability, 
leading to transcriptome signatures that are responsible for cell proliferation, epithelial-to-
mesenchymal transition, chemoresistance, and invasion [86]. Indeed, correlation of 
expression profiles with karyotypic parameters of the NCI-60 cancer cell line panel has 
revealed that CIN is associated with higher expression of genes implicated in epithelial-to-
mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of 
genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance [87]. P53-
dependent pathways (as well as pRB1 pathways) alterations promote epithelial-to-
mesenchymal transition in tumor cells through both CIN licencing and global aberrant 
transcription regulation (reviewed in [88, 89]). Furthermore, proliferation of aneuploid 
human cells is limited by p53 pathway [90]. In support, in genetically engineered mutant 
mice that are prone to aneuploidy TP53 is a limiting factor in aneuploidy-induced 
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tumorigenesis [91]. All together, these data justify reputation of mutant p53 as “the demon 
of the guardian of the genome” [92] and “a master regulator of human malignancies” [93].  
Survivors of hereditary retinoblastoma, a childhood cancer of the eye caused by germline 
mutations of the RB1 tumor suppressor gene, have an elevated risk of developing sarcomas, 
brain cancer, melanoma or some epithelial cancers [94, 95]. It was shown that inactivation of 
the pRB1 pathway in the developing mouse or human retina was accompanied by p19ARF-
p53 pathway activation and RB1-deficient retinoblasts underwent p53-mediated apoptosis 
and exited the cell cycle [96]. In contrast, RB1-deficient cell with inactivated p14ARF-p53 
pathway had growth advantage, clonally expanded, and formed retinoblastoma [96]. As it is 
expected, retinoblastoma is characterized by CIN, strengthening the view that the 
chromosomal changes contribute to the development and progression of malignancy [97, 
98]. Also, analysis of hundreds of chronic lymphocytic leukemias (CLLs) has revealed a 
strong association between RB1 deletion and aberrant p53 pathway with elevated genomic 
complexity, which is a strong independent predictor of rapid disease progression, disease 
aggressiveness, short remission duration, short survival, and therapy efficaciousness in CLL 
[99-101].  
PRB1 plays a critical role in proper chromosome condensation and cohesion, centromeric 
function, and chromosome stability in mammalian cells (reviewed in [102, 103]). Inactivation 
of pRB1 not only allows inappropriate proliferation but also undermines mitotic fidelity 
leading to CIN and ploidy changes [102, 103]. pRB1 pathways deregulation correlates with 
(multi)drug and radioresistance [104, 105]. Screening of more than 25,000 compounds in 
human fibroblasts in which pRB1 activity was compromised by viral oncoproteins revealed 
that the only compounds selective for RB1-deficient cell death were topoisomerase II 
inhibitors (e.g., doxorubicin) [106]. Moreover, RB1-deficient cells displayed increased 
proliferation in the presence of the PI3K (LY294002) and MEK1/2 (U0126) inhibitors [107].  
The CDKN2A locus comprises the INK4A and ARF genes encoding tumor suppressors 
p16INK4A and p14ARF (p19ARF in mice) that up-regulate the activities of pRB1 and p53 
transcription factors, respectively [108]. Inactivation of INK4A, ARF or both genes strongly 
predisposes mice to tumor development (reviewed in [69]). Loss of p16INK4A plays a causal 
role in centrosome dysfunction and the subsequent generation of CIN cells in multiple cell 
types [109]. Furthermore, both CDKN2A and TP53 are rate-limiting for reprogramming of 
somatic cells [110]. CDKN2A or TP53 inactivation has a profound positive effect on the 
efficiency of induced pluripotent stem (iPS) cell generation, increasing both the kinetics of 
reprogramming and the number of emerging iPS cell colonies [110, 111]. Reprogramming of 
somatic cells is accompanied by chromosome abnormalities, point mutations, epigenetic 
changes, and the drastic gene expression changes (reviewed in [112]). CDKN2A or TP53 
inactivation leads to CIN and tumorigenicity of iPS cells (reviewed in [113]). In contrast, iPS 
cells containing an extra copy of the TP53 or CDKN2A show reduced tumorigenic potential 
in various in vitro and in vivo assays and an improved response to anticancer drugs [114]. In 
addition to the reprogramming process itself the (epi)genomic stability of both iPS and 
human embrionic stem cells is affected by in vitro environmental conditions and the 
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techniques used for cell derivation. Also, there is no passage number threshold ensuring 
safety of iPS. However, the risk of abnormalities increases with the time in culture [113].  
PTEN can increase p53 stability and its DNA binding activity through physical association 
with p53 [115]. Germline mutations of PTEN have been found in cancer susceptibility 
Cowden and Bannayan–Riley–Ruvalcaba syndromes, which are now collectively referred to 
as the PTEN hamartoma tumor syndrome. Mice heterozygous for PTEN develop 
spontaneous tumors and conditional tissue-specific disruption of PTEN leads to different 
tumors in the affected tissues (reviewed in [116]). PTEN plays a fundamental role in the 
maintenance of chromosomal stability through the physical interaction with centromeres 
and control of DNA repair. PTEN null cells exhibit extensive centromere breakages and 
chromosomal translocations [117, 118]. Interestingly, comparison of spectra of PTEN and 
TP53 somatic mutations across tumors has revealed that they are usually independent and 
even mutually exclusive [116]. 
Neurofibromatosis type 1 (NF1), a tumor predisposition syndrome, is characterised by the 
growth of benign and malignant tumors involving the peripheral and central nervous 
system and results from inactivating germline mutations of the NF1 gene [119, 120]. NF1 
gene encodes a neurofibromin, which plays a role in MAPK, AKT-mTOR, adenylate cyclase, 
and PKC mediated pathways [121]. One of the main features of neurofibromatosis type 1 is 
benign neurofibromas, 10% of which become transformed into malignant peripheral nerve 
sheath tumors [119]. TP53, CDKN2A, and RB1 mutations or deletions are detected in 
malignant peripheral nerve sheath tumors but not in benign neurofibromas [119, 120, 122]. 
In consistence with it, but in contrast to benign neurofibromas, malignant peripheral nerve 
sheath tumors are caracterized by CIN [119, 122].  
Hyperactivation of the MAPK or PI3K-AKT pathway induces frequently cell cycle arrest 
and senescence in vitro and in vivo. Oncogene-induced senescence program, a state of stable 
cell-cycle arrest, together with oncogene induced apoptosis are recognized to represent an 
important barrier against tumor development in vivo [123]. Senescence cells are 
characterized by the inability to proliferate despite the presence of a steady supply of 
abundant nutrients, mitogens, ample room for expansion, and by maintenance of cell 
viability/resistance to apoptosis and metabolic activity for months. Expression of activated 
forms of RAS (N-RASG12D, H-RASV12, K-RASG12V), B-RAFE600 or MEK was shown to elicit cell 
cycle arrest and senescence in primary fibroblasts, Schwann cells, hepatocytes, T 
lymphocytes, keratinocytes, astrocytes, epithelial intestinal cells and other cell types; AKT 
overexpression induced senescence of primary and immortalized esophageal epithelial cells, 
primary MEFs, primary human aortic endothelial cells, human dermal microvascular 
endothelial cells, and human umbilical vein endothelial cells. Moreover, in vitro and/or in 
vivo inactivation of PTEN, VHL, RB1, NF1 or activation of RHEB, PKC, EGFR, TGFβ, INFβ, 
Cyclin E, Cyclin D, STAT5, c-MYC, β-Catenin, E2F, Rho small GTPases and many other 
proteins triggers senescence (reviewed in [30, 123-126]). Furthermore, mouse embrionic 
fibroblasts deficient in DNA damage response and DNA repair genes (ATM, NBS1, TopBP1, 
BRCA1, BRCA2, Ku86, XRCC4, WRN and ERCC1) undergo premature senescence (reviewed 
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in [125]. Importantly, oncogene-induced senescence is frequently observed in premalignant 
lesions both in animal tumor models and in human patients but is essentially absent in 
advanced cancers, suggesting that malignant tumor cells have found ways to bypass or 
escape senescence [125, 126]. In vitro and in vivo models have shown that senescence and/or 
apoptosis evasion requires p14ARF/p19ARF-p53 and/or p16INK4A-pRB pathway inactivation, 
which results in immortalization and malignant transformation in vitro and invasive tumor 
formation in vivo [30, 123-126].  
The ability to induce CIN after inactivation/hyperactivation is not restricted to cancer genes 
the most frequently mutated across cancer types. BCR-ABL oncogene is mainly associated 
with Philadelphia chromosome positive chronic myeloid leukemia (>90% of patients) but is 
also found in acute lymphoblastic leukemia and occasionally in acute myelogenous leukemia. It 
results from a reciprocal translocation between chromosome 9 and 22. BCR-ABL is engaged 
in multiple signaling pathways and its expression in cells induces CIN (reviewed in [127, 
128]). Heterozygous germline mutations in tumor supressors BRCA1 or BRCA2 are 
associated with hereditary cancers (e.g., breast and ovarian). BRCA1 and BRCA2 proteins 
have multiple functions including participating in a pathway that mediates repair of DNA 
double strand breaks by error-free methods. Inactivation of BRCA1 or BRCA2 results in 
centrosome amplification, cell-cycle checkpoint defects, DNA damage and CIN (reviewed in 
[129-131]). Von Hippel-Lindau disease is caused by germline mutations in the VHL tumour 
suppressor gene. VHL mutations predispose to the development of a variety of tumors 
(reviewed in [132]). Loss of VHL causes the mitotic spindle misorientation and CIN 
(reviewed in [133, 134]). Adenomatous polyposis coli (APC) was identified as a tumor 
suppressor gene mutated in familial colon cancer. Now it is well documented that loss of 
APC function plays an important role in CIN induction (reviewed in [135, 136]). Ataxia 
telangiectasia syndrome is characterized by extreme sensitivity to radiation, cell-cycle 
checkpoint defects, CIN, and predisposition to cancer. The disease is caused by germline 
mutations in the ATM gene involved in DNA double-strand break signaling and repair 
(reviewed in [137, 138]). Multiple endocrine neoplasia type 1 (MEN1) is an inherited cancer 
predisposition syndrome characterized by development of tumors in both endocrine and 
nonendocrine organs in patients and a mouse model of MEN1 [139]. MEN1 encodes a tumor 
suppressor menin participating in regulation of cell proliferation, apoptosis, and DNA 
damage response/genome stability in part localizing to the promoters of thousands of 
human genes and regulating transcription mediated by interactions with chromatin 
modifying enzymes (reviewed in [140, 141]). Aberrant MYC activity is associated with the 
appearance of DNA damage-associated markers and CIN (reviewed in [142, 143]).  
Furthermore, in vitro and in vivo research has proven that dozens of proteins involved in 
regulation of chromosome cohesion, centrosome amplification, spindle assembly 
checkpoint, kinetochore-microtubule attachment, cell cycle as well as homologous and non-
homologous recombination can trigger centrosome amplifiction and CIN in primary or 
chromosomaly stable immortalized cells and induce tumors in genetically engineered mice 
(reviewed in [144-148] “offering proof of principle that CIN alone can be the root cause of 
spontaneous tumors in mammals” [71]. Moreover, diverse growth factors, transmembrane 
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receptors, transcription factors when extopically overexpressed in cells also trigger 
centrosome amplification and CIN and are able to transform cells. Also, there is a significant 
association between global hypomethylation and CIN [149-153]. DNA methyltransferase 
deficient cells are chromosomally unstable [154, 155], and mice models have demonstrated 
that genomewide DNA hypomethylation can induce tumors [156-158]. Thus, a specific effect 
of oncoproteins is to cause aneuploidization [50] and the elevation of stochastic CIN [10].  
5. All roads lead to centrosome 
In cancer cells mechanism of centrosome amplification and clustering is proposed to be the 
major contributor to CIN [159, 160]. Centrosomes are microtubule-organizing structures that 
determine the organization of the mitotic spindle poles that segregate duplicated 
chromosomes between dividing cells. Mechanistically, CIN is driven by bipolar spindle 
formation through centrosomal clustering, which increases the formation of merotelic 
attachments (an error in which a single kinetochore is attached to microtubules emanating 
from both spindle poles [161]) producing chromosome missegregation [159, 160]. 
Chromosome missegregation was widely considered to occur due to anaphase lagging 
chromosomes. Nevertheless, recently it has been evidenced that most lagging chromosomes 
end up in the correct daughter cell, and the largest contribution to missegregation without 
obvious lagging in anaphase makes chromosomes with multimerotelic kinetochores, those 
with many microtubules oriented toward the wrong pole [162]. Centrosomal clustering 
allows successful completion of a cell division. In contrast, progeny of rarely and 
spontaneously arising multipolar cell divisions are often unviable undergoing mitotic cell 
death or cell-cycle arrest [159]. Whole-chromosome segregation errors frequently results in 
double-strand breaks, which can lead to unbalanced translocations in the daughter cells 
[163, 164] and chromosome pulverization/ chromothripsis defined by small-scale DNA copy 
number changes and extensive inter- and intrachromosomal rearrangements [165, 166]. 
Structural chromosomal aberrations lead to loss of heterozygosity for tumor suppressor 
genes [165, 167-170]. The transplantation of the generated Drosophila larval neural stem cells 
with extra centrosomes in normal hosts can induce the formation of metastatic tumors [171]. 
Centrosome abnormalities have been reported in most cancers. 
Centrosome is made up of and regulated by more than 350 proteins (reviewed in [172-174] 
and numerous additional centrosome component candidates were revealed [175]. Genome-
wide RNA interference screens have confirmed that about 200 genes contribute to spindle 
assembly [176], 32 genes are involved in centriole duplication and centrosome maturation 
[177], and 133 genes are engaged in centrosome clustering in drosophila cells [178]; silencing 
of 82 genes has resulted in the prevention of spindle multipolarity in human oral squamous 
cell carcinoma cells with supernumerary centrosomes [179]. Moreover, a system-wide two-
hybrid screen on 94 proteins implicated in spindle function in Saccharomyces cerevisiae has 
uncovered 604 protein-protein interactions [180], and a cell cycle phosphoproteome of 18 
yeast centrosome proteins has identified 297 phosphorylation sites [181]. Thus, accounting 
only these figures and that all these genes/proteins are regulated on multiple levels and 
changes of the abundance or activity of any one will affect the whole process, it is easy to 
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understand why introduction of an oncogene into a cell directly or indirectly but inevitably 
will result in CIN. Indeed, monitoring phosphorylation of the histone variant H2AX, an 
early mark of DNA damage, it was identified hundreds of genes whose downregulation led 
to elevated levels of H2AX phosphorylation [182], and screening of 2,000 reduction-of-
function alleles (1038 genes) for 90% of essential genes in Saccharomyces cerevisiae has 
generated a catalogue of 692 CIN genes whose disruption may lead to CIN [183]. Enriched 
gene ontology together with sequence orthologs created a list of human CIN candidate 
genes, which, when was cross-referenced to published somatic mutation databases, revealed 
hundreds of mutated CIN candidate genes [183].  
Thus, irrespectively of their functions oncogenes and tumor suppressors directly or 
indirectly converge on centrosomes and mitotic checkpoints (reviewed in [144, 147, 148]). 
Deregulation of oncogenic and tumor suppressor pathways triggers and collaborates with 
CIN during tumorigenesis [184]. In contrast, supernumerary centrosome formation and CIN 
is reduced by overexpression of tumor suppressors in CIN cells [185-188]. Relationship 
between CIN and cancer genes explains well why such large number of cancer genes was 
identified (487 genes, data on September 2012) and why hundreds of oncogenes with 
diverse functions, when are ectopically overexpressed, are characterized by the same ability: 
to transform a cell or aggravate tumorigenicity.  
6. CIN induction: Beyond cancer genes 
CIN/aneuploidy induction is not restricted to cancer genes. Exposure of cells to drugs, 
chemical agents, and physical influences, as well as contacts with bacterial cells and 
infection with some viruses do induce centrosome amplification, CIN and can eventually 
result in transformation or aggravate transformed phenotype.  
Metals in general are considered to be weak mutagens, if mutagenic at all, still many metals 
are carcinogenic (reviewed in [9, 189]). All of the carcinogenic metals are able to induce CIN. 
It was systematically shown that carcinogenic metals cause centrosome amplification, 
centriolar defects, spindle assembly checkpoint bypass, suppression of the dynamic 
instability of microtubules (reviewed in [189, 190]). Non-mutagenic carcinogen asbestos 
causes centrosome amplification and CIN [191] by binding to a subset of proteins that 
include regulators of the cell cycle, cytoskeleton, and mitotic process [192]. Non-mutagenic 
carcinogens polycyclic aromatic hydrocarbons including dioxins or benzo[a]pyrene also 
provoke CIN [9]. One of the possible mechanisms is through activation of a cytoplasmic 
aryl hydrocarbon receptor (reviewed in [193]), which itself when is ectopically 
overexpressed can induce centrosome amplification [194]. Nanomaterials give rise to 
aneuploidy mainly by interfering with microtubules (reviewed in [195]). Both intestinal 
commensal Enterococcus faecalis and pathogen Helicobacter pylori are potential important 
contributors to the etiology of sporadic colorectal cancers and can contribute to cellular 
transformation and tumorigenesis triggering DNA double breaks and CIN [196, 197]. 
Human papillomavirus oncoproteins E6 and E7 induce centrosome abnormalities and 
CIN (reviewed in [198]).  
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Thus, any factor, genetic or non-genetic, internal or external, producing stress-induced 
genome system instability and its mediated increase in the cell population heterogeneity 
will contribute to cancer evolution [5, 6].  
7. Oncogene addiction concept 
The term “oncogene addiction” was first coined by B. Weinstein to describe the dependency 
of certain tumor cells on a single activated oncogenic protein or pathway to maintain their 
malignant properties, despite the likely accumulation of multiple gain and loss-of-function 
mutations that contribute to tumorigenicity. Decoding oncogene addiction in cancer is 
believed to provide a key for effective molecular targeted therapy [199-204]. The concept of 
oncogene addiction has been obtained from various human tumor-derived cell lines and 
conditional transgenic animal models in which acute inactivation of the overexpressed wild 
type (e.g., MYC and WNT1) or mutated oncogenes (e.g., EGFR, K-RAS, H-RAS, B-RAF, MET, 
FGFR3, ALK, AURK, and RET) via switching off an inducible oncogene, siRNA, or small-
molecule inhibitors typically has resulted in rapid apoptosis, or sometimes growth arrest 
and differentiation of tumor cells causing regression of the tumor [199-201, 206, 207]. 
However, many research groups monitoring long-term tumor response in diverse 
conditional mice models after oncoprotein withdrawal have repeatedly observed tumor 
relapses: H-RAS and p16INK4A-/- (melanoma model), HER2/NEU (mammary carcinoma 
model), BCR-ABL (acute B-cell lymphoma model) (reviewed in [206]), MYC (lymphoma and 
mammary carcinoma models) [206, 208, 209], WNT1 (mammary carcinoma model) [206, 208, 
210], MYC and K-RAS (mammary carcinoma model) [207], K-RAS and MAD2 (lung 
carcinoma model) [211], K-RAS (glioma model) [212] (see also [50] for additional examples), 
supporting the statement that “the nature of the initiating oncogene appears to be of little 
influence on the response of the resulting tumors to oncogene inactivation” [211]. In many 
cases tumor escape from oncogene dependence upon the primary oncogene inactivation 
was attributed to the acquired diverse novel genetic lesions [206, 211]. For example, MYC-
induced lung cancers after oncogene inactivation failed to regress completely because of 
secondary activating events in K-RAS associated pathways [212] and the loss of TP53 
resulted in the absence of tumor regression [213], whereas loss of one TP53 allele 
dramatically facilitated the progression of WNT1-induced mammary tumors to a oncogene 
independent state both by impairing the regression of primary tumors and by promoting 
the recurrence of fully regressed tumors following oncogene inactivation [214]. The 
acquisition of oncogene independence and tumor recurrence in K-RAS glioma model 
coincided with loss of CDKN2A [215]. Concurrent mutational inactivation of the PTEN and 
RB1 tumor suppressors was determined as a mechanism for loss of B-RAF/MEK 
dependence in melanomas harboring B-RAF mutations [216]. Loss-of-function mutations in 
PTEN genes rendered T cell acute lymphoblastic leukemia independent of the MYC 
oncogene in conditional zebrafish model [209]. It is worth recalling that TP53, RB1, 
CDKN2A, K-RAS, and PTEN are among the most frequently mutated genes in human 
tumors [3]. It follows that advanced tumors already harbour “escape mechanisms”!  
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Importantly, acquisition of novel genetic lesions as primary oncogene dependence escape 
mechanisms is accompanied by CIN in tumor models. Analysis of relapsed lymphomas 
after MYC de-induction in conditional mice model showed that every relapsed tumor 
exhibited additional chromosomal rearrangements, both numerical and structural, 
compared with the primary tumor of origin [217] and high levels of aneuploidy in the 
primary tumor and in remaining cells survived after K-RAS and MAD2 oncoproteins 
withdrawal correlated with lung tumor relapses [218].  
Observation of tumor relapses after oncogene inactivation and unsuccess of targeted 
therapies in multiple diverse clinical trials inclined many researchers to accept the pitfalls of 
oncogene addiction concept [6, 199, 200, 202, 211, 219-222]. Majority of tumors contain a 
heterogeneous cell population with a number of stochastic genome alterations, extensively 
rewired signaling networks and addicted to multiple oncogenes [6, 200, 220]. Furthermore, 
the addicted states can easily switch with each other during cancer progression and in 
particular during medical intervention [5, 202]. It is proposed that the concept of “network 
addiction”, rather than “oncogene addiction”, recapitulates more closely what is happening 
during tumor development and after exposure to therapeutic agents [219]. There is no 
particular pathway that would play a prominent role in maintaining cell viability [221]. For 
example, over 100 altered signaling pathways were identified in squamous cell lung 
carcinoma [222]. Illusion of oncogene dependence [199] and limited relevance of oncogene 
addiction concept for the majority of tumors [211] led to eradication of the hope of targeting 
the key addictive oncogene that maintains one’s cancer [220]. Really, the obvious success of 
targeted therapy based on oncogene addiction concept is mainly restricted only to chronic 
myelogenous leukaemia (CML) in clinic [22, 223], which possesses in chronic phase, a major 
phase of drug response, a homogeneous population of tumor cells arisen from a single 
driver mutation, although still with high frequency of resistance development (35% of 
patients in chronic phase treated with imatinib) [224, 225].  
Oncogene addiction concept and models, which it has been derived from, have obvious 
shortcomings and pitfalls. Cell lines display a genetic drift and low heterogeneity different 
from tumors in vivo as a consequence of selection and adaptation for cell culture conditions 
[226, 227]. Numerous tissue-specifc genetically engineered mouse cancer models have been 
developed that exhibit many biologic hallmarks of human cancer (reviewed in [69, 228]), 
however, they still poorly reproduce spontaneous tumors (reviewed in [229]). In transgenic 
mice models all the cells share the same genetic defects, which can not be the case in most 
sporadic cancers. Activated oncogenes form a dominant pathway through artificial selection 
favoring cancer progression and promoting cancer evolution much more strongly than what 
occurs in nature. It results in drastically reduced genome heterogeneity, which helps 
investigators illustrate the importance of favored genes [6]. Limited number of initiating 
genetic alterations, artificially activated oncogenes, benign levels of CIN, intratumor genetic 
homogeneity, and fostered evolution make mice tumors inappropriate models for the 
targeted treatment of cancers [6, 50, 218, 229]. Cancer therapy based on oncogene addiction 
concept is palliative rather than curative in clinic [22]. Also, the uniqueness and significance 
of oncogene addiction concept should be questioned by a growing list of non-oncogenes 
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that are not inherently oncogenic themselves (not mutated or altered in any way) but 
required for tumor initiation and maintenance in a variety of cancer models [230-234]. This 
has led to establishment of non-oncogene addiction concept (reviewed in [233]).  
Now it is supposed that insights into tumor evolution and the changes of tumor 
heterogeneity upon targeted therapy will allow identifying the non-responsive clones and 
targeting them [235-237]. However, underestimated intratumor heterogeneity can be a 
serious obstacle making this strategy hardly clinically implementable [15-20, 238].  
8. Conclusion 
Solid tumor evolution is cyclical and consists of two distinct phases: a punctuated phase 
(high CIN, frequent non-clonal chromosome aberrations) and a stepwise phase (low CIN, 
clonal evolution with dominant clonal chromosome aberrations). Shifts between phases are 
induced by stress and subsequent selection [5, 6, 10]. Thus, severity of CIN can be changed 
during tumour evolution and is affected by diverse genetic and non-genetic, internal and 
external stresses (modulation of expression of cancer genes, drugs, chemical 
agents/carcinogens, physical influences, and microenvironment changes). CIN results in 
genomic and (epi)genetic heterogeneity facilitating evolution of cancers and creating 
multiclonal tumour architecture, which increases the chance of pre-existance before or 
appearance during therapy of resistant sublones. There is a significant correlation in 
primary tumors between the degree of CIN and treatment sensitivity, the risk of acquired 
resistance and further tumor relapses. p14ARF-p53 and p16INK4A-pRB pathways are the main 
safeguards of mitotic fidelity. Once p14ARF-p53 or/and p16INK4A-pRB pathway is 
compromised, CIN is unleashed. Oncogene/stress induced senescence or apoptosis evasion 
requires p14ARF/p19ARF-p53 and/or p16INK4A-pRB pathway inactivation, which results in 
successful immortalization and malignant transformation in vitro and invasive tumor 
formation in vivo. Consequently, increasing both the kinetics of reprogramming and the 
number of emerging iPS cell colonies by disrupting CDKN2A or TP53 will inevitably result 
in transformation.  
CIN and the resulting clonal/non-clonal intratumor heterogeneity elucidate why large-scale 
tumor genome sequencing and high-resolution analysis of somatic copy-number alterations 
have failed to reveal “universal” cancer genes except well known for decades (TP53, 
CDKN2A, RB1, PIK3CA, KRAS, and NF1), and type- and stage-specific recurrent aberrations 
in solid tumors, whereas most recurrent chromosome abberations (deletions, amplifications, 
and translocations) ever ocurring genome-wide in tumors can be explained by 3D genome 
organization, spatial proximity among chromosome loci, and replication timing of sites 
producing rearrangements [239-241]. CIN explains how non-mutagenic chemical agents, 
physical influences, contacts with bacterial cells, and infection with some viruses induce or 
promote transformation of cells in vitro and tumor development in vivo, as well as 
spontaneous in vitro transformation of primary and immortalized cells and tumorigenicity 
of induced pluripotent stem (iPS) cells. CIN accounts for the acquisition of oncogene 
independence and tumor recurrence after inductor withdrawal in oncogene on/off 
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conditional transgenic mice models. CIN and intratumor heterogeneity are the reasons of 
oncogene addiction independence of solid tumors from any particular oncogene and general 
ineffectiveness of targeted therapy in clinic. Any factors or stresses that contribute to CIN 
can potentially promote the evolution of cancer.  
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